A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs AbGn 7 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Carcinoma; Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Jul 2013, as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top